• Home
  • Science
    • ImmunoBody®
    • Moditope®
    • Glymab®
    • Publications
  • Pipeline
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Contact Us
    • Find a trial
    • Become an Investigator

SCOPE Phase 2 Trial Data Update, ESMO December 2025

by chantal | Dec 11, 2025 | Immunobody, iSCIB1+, SCIB1, Vaccines

European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 10-12 December 2025 in London

by chantal | Dec 10, 2025 | iSCIB1+, SCIB1, Vaccine, Vaccines

Kate Young, Samantha Paston, Heather Shaw, Pippa Corrie, Sarah Danson, Miranda Payne, Poulam Patel, Ioannis Karydis, Satish Kumar, Clare Barlow, Rebecca Lee, Martin Highley, Kellati Prasad, Georgia Goodhew, Gaëlle Cane, Joseph Chadwick, Sabaria Shah, Nermeen Varawalla...

SCOPE Study Poster, ESMO Immuno-Oncology Congress December 2025

by chantal | Dec 9, 2025 | Immunobody, iSCIB1+, SCIB1

Heather Shaw, Poulam Patel, Miranda Payne, Satish Kumar, Sarah Danson, Martin Highley, Clare Barlow, Kellati Prasad, Ioannis Karydis, Maria Marples, Kate Young, Pippa Corrie, Robert Miller, Georgia Goodhew, Samantha Paston, Gaelle Cane, Joe Chadwick, Lindy Durrant and...

Scancell updated Phase 2 data shows continued improvement in progression free survival with iSCIB1+

by chantal | Dec 9, 2025 | iSCIB1+, Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Abundant development opportunities in immuno-oncology

by chantal | Nov 17, 2025 | Immunobody, iSCIB1+, Moditope, SCIB1, Trinity Delta Reports

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
« Older Entries
Next Entries »

Recent Posts

  • Active Immunotherapy: Ready For Prime Time
  • Strategic transactions to unlock longer-term value
  • Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing
  • iSCIB1+ pivotal trial plans advancing
  • AACR (American Association for Cancer Research) Annual Meeting, April 2026, San Diego, California

Recent Comments

No comments to show.

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

ACTIVE IMMUNOTHERAPY

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®
AvidiMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy